Clinical Trials Logo

Ablation clinical trials

View clinical trials related to Ablation.

Filter by:

NCT ID: NCT06231160 Not yet recruiting - Clinical trials for Pancreatic Neoplasms

Clinical Comparative Study of Systematic Therapy Combined With MWA and Systematic Therapy for Pancreatic Cancer

Start date: February 1, 2024
Phase:
Study type: Observational

Pancreatic carcinoma (PC) is the deadliest malignant tumors worldwide. Surgical resection is one of the most effective methods for the treatment of PC, but the resectable rate is less than 20% among the patients with PCs, and the recurrent and metastatic rate is more than 80% in two years after resection. Ablation has been confirmed one of the most effective methods for solid tumors by recent twenty years and proven to be a radical treatment similar to the surgical resection for the clinical applications of hepatic and renal tumors at early clinical staging in the internationally guidelines. The purpose is to explore the efficacy and safety of microwave ablation in the treatment of pancreatic cancer in combination with systematic therapy.

NCT ID: NCT06172699 Recruiting - Cardiac Arrhythmia Clinical Trials

Assert-IQ Implantable Cardiac Monitor (ICM) Post Market Study

Assert-IQ
Start date: January 1, 2024
Phase:
Study type: Observational

This is a prospective, non-randomized, multi-center, real-world post-market study to collect and evaluate data regarding the performance of the enhanced atrial fibrillation detection algorithm of the Assert-IQTM Implantable Cardiac Monitor (ICM) device.

NCT ID: NCT06134739 Recruiting - Atrial Fibrillation Clinical Trials

Arterial Embolism After Catheter Ablation of Atrial Fibrillation. ATRIAL FIBRILLATION

EMBOL-AF
Start date: January 2, 2024
Phase:
Study type: Observational

The EMBOL-AF is a multicenter, international, observational study designed as a retrospective registry that will investigate the characteristics of systemic arterial embolic events after treatment of atrial fibrillation by catheter ablation. Due to the retrospective nature of the study, the registry is specially focused on cerebral embolism (stroke and TIA) because these are not only the most frequent and clinically relevant but also the most susceptible to underreporting. However, all embolism associated to AFAbl will be included. This study will gather all clinically relevant aspects and data of all cases of arterial embolism that have occurred over the last 5 years in the centers that will participate in the registry. Based on these reported cases, the incidence, management and outcomes of embolic events (particularly stroke and TIA) will be studied.

NCT ID: NCT05848635 Not yet recruiting - Ablation Clinical Trials

Hydromorphone for Perioperative Analgesia in Lung Tumor Ablation Parallel Controlled

Start date: May 1, 2023
Phase: Phase 4
Study type: Interventional

This randomized, parallel controlled, single blind trial is designed to evaluate the efficacy and safety of hydromorphone versus morphine for perioperative analgesia in lung tumor ablation.

NCT ID: NCT05698576 Recruiting - Prostate Cancer Clinical Trials

TRANBERG® Transperineal MR/US Fusion Laser--Induced Thermal Therapy for Men With Prostate Cancer

TPF-LITT
Start date: March 16, 2022
Phase: N/A
Study type: Interventional

This study is set up as a phase I prospective, single center, device interventional pilot study carried in office setting under local anesthesia. It will assess the tolerance and safety of target fusion ablation of prostate cancer tumors using Laser Induced Thermal Therapy (TFA-LITT) guided by fusion imaging in men 50 to 80 years of age with low to intermediate risk prostate cancer Prostate Cancer is currently managed with in a discrete fashion where patients either enroll in active surveillance protocols (No intervention) or undergo full intervention via whole gland treatments - most commonly radical surgery or radiation. These treatments have not shown definitive gains in all cause survival and not uncommonly harbor undesirable adverse effects, most notably: impotency and incontinence. Such events elicit significant and noticeable changes on a male lifestyle and for most prostate cancer tumors are considered overtreatment. This study aims to evaluate the use of TFA-LITT in the office setting under local anesthesia - greatly decreasing patient perioperative surgical risk - focused on the organ sparing cancer lesion ablation, where organ function is preserved. The fundamental objective is to determine the tolerance and safety of TFA-LITT in men with low to intermediate risk prostate cancer, successful performed in the outpatient office-based setting under local anesthesia directed by fusion imaging. Secondary objectives include: 1-Biopsy proven cancer control of ablated areas 12 months after procedure; 2-Uroflowmetry and urinary function Patient Reported Outcome Measures (PROMs) at one, three, six, nine and 12 months; 3- Sexual function Patient Reported Outcome Measures (PROMs) at one, three, six, nine and 12 months; 4- MRI changes of ablated area one, three and 12 months after TFA-LITT; 5- Absence or presence of ejaculation after TFA-LITT.

NCT ID: NCT05498779 Completed - Clinical trials for Hepatocellular Carcinoma

Ablation of Hepatocellular Carcinoma: a Nationwide Study

Start date: June 1, 2022
Phase:
Study type: Observational

Background Hepatocellular carcinoma (HCC) is the most common primary malignancy in the liver. Chronic infection with hepatitis C virus (HCV) is a significant risk factor and may be associated with inferior outcome. According to the Danish national guidelines, ablation should be offered patients with early HCC (tumor < 3 cm) in a cirrhotic liver, who are not transplant candidates. However, the effect of size of the HCC tumor and Hepatitis C virus (HCV) as etiology are insufficiently investigated. Purposes 1. Investigate association between HCC tumor size and survival and recurrence after ablation. 2. Investigate survival and recurrence after ablation in patients with HCV-related HCC compared with HCC due to other etiologies. Methods This study is based on data from the Danish Liver and Bile Duct Cancer Database (DLGCD) and the Danish Database for Hepatitis B and C (DANHEP) and the laboratory database (DANVIR), which collectively include information on patient characteristics, tumor characteristic, laboratory results, and information regarding ablation, HCV status, and antiviral treatment, respectively. Perspectives Ablation has been widely used for decades, but studies investigating the effect of ablation for HCC in patients with HCV and size of HCC are lacking. This study will contribute considerably to the level of evidence and may impact both Danish and international guidelines for HCC treatment.

NCT ID: NCT05270642 Active, not recruiting - Clinical trials for Hepatocellular Carcinoma

Plan for Microwave Thermal Field

Start date: October 1, 2021
Phase: N/A
Study type: Interventional

Develop an intelligent system based on contrast-enhanced ultrasound and clinical information to help doctors automatically obtain ablation parameters (ablation needle number, ablation needle type, ablation time,ablation power) when preparing to use microwave ablation to treat hepatocellular carcinoma

NCT ID: NCT05257694 Recruiting - Clinical trials for Hepatocellular Carcinoma

Clinical Decision Biological Biomarker and Prognosis Prediction of Hepatocellular Carcinoma by Deep Learning

Start date: January 1, 2022
Phase:
Study type: Observational

Developing a deep learning model based on contrast-enhanced ultrasound (CEUS) to predict the prognosis of hepatocellular carcinoma (HCC) and aid choose operation decisions

NCT ID: NCT05073744 Recruiting - Safety Clinical Trials

Nalbuphine Versus Morphine for Perioperative Tumor Ablation

Start date: September 5, 2021
Phase: Phase 4
Study type: Interventional

This randomized, positive control, multicentre trial is designed to compare the analgesic efficacy and safety of nalbuphine hydrochloride injection and morphine hydrochloride injection for perioperative tumor ablation.

NCT ID: NCT04893278 Enrolling by invitation - Ablation Clinical Trials

Virtual Reality in Electrophysiology Laboratory (EP)

Start date: July 31, 2021
Phase:
Study type: Observational

The purpose of this study is to evaluate the use of virtual reality (VR) technology as adjunct to routine anesthesia care for patients undergoing electrophysiology (EP) procedures.